Phenotype measures set:   Wiltshire4   Bcells_Sel

ID, description, units MPD:52461   Bcells_Sel   B cells, percent viability   [%]
selumetinib study
Measures • dose [µM]:    • control    • 0.046    • 0.137    • 1.235    • 11.1    • 100
Data set, strains Wiltshire4   inbred w/CC7   34 strains     sex: m     age: 10wks
Procedure immune cell quantification
Comparisoncontrol group vs. multiple treatment / dosage groups
Ontology mappings

  SIDE-BY-SIDE STRAIN CURVES
Values
Graph Type
Dimensions Width:  ×  Height: px
Plot Options


  OVERLAPPING STRAIN CURVES
Data
Dimensions px
Toggle Series   
Plot Options

Wiltshire4 - B cells, percent viability





  ANOVA, Q-Q NORMALITY ASSESSMENT

ANOVA Summary     

Factor DF Sum of squares Mean sum of squares F value p-value (Pr>F)
dose 5 11164.0764 2232.8153 4.7676 0.0003
strain 33 77575.3958 2350.7696 5.0195 < 0.0001
dose:strain 165 79913.6285 484.325 1.0342 0.3844
Residuals 594 278185.8423 468.3263

Q-Q normality assessment based on residuals

  


  INDIVIDUAL MEASURES
ProjectIDDrug or
challenge
Description and varname PanelStrains
tested
SexAge
Wiltshire4 52461 immune cell quantification selumetinib B cells, percent viability   [%]   control   Bcells_Sel_ctrl inbred w/CC7 34 m 10wks
Wiltshire4 52462 immune cell quantification selumetinib B cells, percent viability   [%]   dose: 0.046 µM   Bcells_Sel_A inbred w/CC7 34 m 10wks
Wiltshire4 52463 immune cell quantification selumetinib B cells, percent viability   [%]   dose: 0.137 µM   Bcells_Sel_B inbred w/CC7 34 m 10wks
Wiltshire4 52464 immune cell quantification selumetinib B cells, percent viability   [%]   dose: 1.235 µM   Bcells_Sel_C inbred w/CC7 34 m 10wks
Wiltshire4 52465 immune cell quantification selumetinib B cells, percent viability   [%]   dose: 11.1 µM   Bcells_Sel_D inbred w/CC7 34 m 10wks
Wiltshire4 52466 immune cell quantification selumetinib B cells, percent viability   [%]   dose: 100 µM   Bcells_Sel_E inbred w/CC7 34 m 10wks